A press release from Skyhawk Therapeutics announces nine month interim results in patients from its Phase 1 clinical trial of SKY-0515 as a treatment for Huntington’s Disease.
See the full article here: https://hdsa.org/wp-content/uploads/2026/01/FOR-RELEASE-Skyhawk_SKY-0515-Nine-Month-Phase-1C-Patient-Data-1-27-26.pdf
